International Journal of Molecular Sciences (Aug 2022)

Reduction of Emphysema Severity by Human Umbilical Cord-Derived Mesenchymal Stem Cells in Mice

  • Vincent Laiman,
  • Yueh-Lun Lee,
  • Yu-Wei Hou,
  • Yu-Ting Fang,
  • You-Yin Chen,
  • Yu-Chun Lo,
  • Didik Setyo Heriyanto,
  • Shu-Chi Lan,
  • Chia-Ling Chen,
  • Xiao-Yue Chen,
  • Kang-Yun Lee,
  • Jer-Hwa Chang,
  • Hsiao-Chi Chuang

DOI
https://doi.org/10.3390/ijms23168906
Journal volume & issue
Vol. 23, no. 16
p. 8906

Abstract

Read online

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in chronic lung disease patients throughout the world. Mesenchymal stem cells (MSCs) have been shown to regulate immunomodulatory, anti-inflammatory, and regenerative responses. However, the effects of human-umbilical-cord-derived mesenchymal stem cells (hUC-MSCs) on the lung pathophysiology of COPD remain unclear. We aimed to investigate the role of hUC-MSCs in emphysema severity and Yes-associated protein (Yap) phosphorylation (p-Yap) in a porcine-pancreatic-elastase (PPE)-induced emphysema model. We observed that the emphysema percentages (normalized to the total lung volume) measured by chest computed tomography (CT) and exercise oxygen desaturation were significantly reduced by hUC-MSCs at 107 cells/kg body weight (BW) via intravenous administration in emphysematous mice (p 6 and 107 cells/kg BW (p +) lymphocytes by PPE were significantly reversed by hUC-MSC administration in emphysematous mice (p 6 and 107 cells/kg BW (p p p < 0.05). In conclusion, the administration of hUC-MSCs improved multiple pathophysiological features of mice with PPE-induced emphysema. The effectiveness of the treatment of pulmonary emphysema with hUC-MSCs provides an essential and significant foundation for future clinical studies of MSCs in COPD patients.

Keywords